PT Darya-Varia Laboratoria Tbk Stock

Equities

DVLA

ID1000117203

Pharmaceuticals

End-of-day quote INDONESIA S.E. 06:00:00 2024-04-23 pm EDT 5-day change 1st Jan Change
1,415 IDR 0.00% Intraday chart for PT Darya-Varia Laboratoria Tbk -4.39% -15.02%
Sales 2022 1,917B 119M Sales 2023 1,891B 117M Capitalization 1,865B 116M
Net income 2022 149B 9.26M Net income 2023 146B 9.07M EV / Sales 2022 1.2 x
Net cash position 2022 355B 22.02M Net cash position 2023 239B 14.79M EV / Sales 2023 0.86 x
P/E ratio 2022
17.8 x
P/E ratio 2023
12.7 x
Employees 1,269
Yield 2022
5.02%
Yield 2023
-
Free-Float 7.87%
More Fundamentals * Assessed data
Dynamic Chart
PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the Full Year Ended December 31, 2023 CI
PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the Half Year Ended June 30, 2023 CI
PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the Full Year Ended December 31, 2022 CI
PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the Half Year Ended June 30, 2022 CI
PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the Full Year Ended December 31, 2021 CI
PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Pt Darya-Varia Laboratoria Tbk Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Pt Darya-Varia Laboratoria Tbk Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Pt Darya-Varia Laboratoria Tbk Reports Earnings Results for the Half Year Ended June 30, 2020 CI
PT Darya-Varia Laboratoria Tbk Launches New Variant, Natur-E White Series CI
Pt Darya-Varia Laboratoria Tbk Reports Earnings Results for the Full Year Ended December 31, 2019 CI
More news
1 week-4.39%
Current month-3.08%
1 month+1.80%
3 months-16.76%
6 months-27.06%
Current year-15.02%
More quotes
1 week
1 410.00
Extreme 1410
1 470.00
1 month
1 400.00
Extreme 1400
1 530.00
Current year
1 375.00
Extreme 1375
1 720.00
1 year
1 375.00
Extreme 1375
2 110.00
3 years
1 375.00
Extreme 1375
3 400.00
5 years
1 375.00
Extreme 1375
3 400.00
10 years
1 160.00
Extreme 1160
3 400.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 20-09-30
Director of Finance/CFO 55 22-06-27
Chairman 53 04-12-31
Members of the board TitleAgeSince
Chairman 53 04-12-31
Director/Board Member 62 05-05-31
Director/Board Member 56 19-06-10
More insiders
Date Price Change Volume
24-04-24 1,415 0.00% 8,700
24-04-23 1,415 -1.74% 41,400
24-04-22 1,440 +0.70% 20,900
24-04-19 1,430 -2.72% 20,000
24-04-18 1,470 -0.68% 66,500

End-of-day quote INDONESIA S.E., April 23, 2024

More quotes
PT Darya-Varia Laboratoria Tbk is an Indonesia-based pharmaceutical company. Its segments include prescription drugs, consumer health products, export and toll manufacturing services and services. Its consumer health products include skin nutrition, respiratory, vitamins and daily relief. Its prescription products include Daryaven, Urdafalk and Aspilets. Through its multivitamin brands, such as Enervon-C, Enervon Active, Enervon Gold and Supertin, it helps to boost body immune and maintain health. It also provides Imunped as a supplement for kids with Zinc and vitamin C, which are essential for children. Its Forti-D 1000 IU is a health supplement (vitamin) product. Fortagyl provides prevention and treatment of amoebiasis, trichomoniasis, giardiasis and post-operation infections. It provides toll manufacturing services for both local and international principals with its two manufacturing facilities: Gunung Putri and Citeureup manufacturing facilities.
More about the company